Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-22T08:34:29.410Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive dyskinesia: motor system impairments, cognition and everyday functioning

Published online by Cambridge University Press:  07 September 2017

Martin Strassnig Open the ORCID record for Martin Strassnig [Opens in a new window] ,
Amie Rosenfeld  and
Philip D. Harvey
Martin Strassnig*
Affiliation:
Department of Integrated Medical Science, Florida Atlantic University, Charles Schmidt College of Medicine, Boca Raton, Florida
Amie Rosenfeld
Affiliation:
Department of Integrated Medical Science, Florida Atlantic University, Charles Schmidt College of Medicine, Boca Raton, Florida
Philip D. Harvey
Affiliation:
Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida
*
*Address correspondence to: Martin Strassnig, Department of Integrated Medical Science, Florida Atlantic University, Charles Schmidt College of Medicine, 777 Glades Road, Boca Raton, Florida 33431. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.

Keywords

Tardive dyskinesiamotor functioncognitionphysical performancedisability
Type
Review
Information
CNS Spectrums , Volume 23 , Special Issue 6: Theme: Neuropsychiatry , December 2018 , pp. 370 - 377
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Haro, JM, Salvador-Carulla, L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006; 20(4): 293–301.Google Scholar
2. Lerner, V, Miodownik, C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? a modern treatment. Curr Psychiatry Rep. 2011; 13(4): 295–304.Google Scholar
3. Merrill, RM, Lyon, JL, Matiaco, PM. Tardive and spontaneous dyskinesia incidence in the general population. BMC Psychiatry. 2013; 13: 152. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681708/. Accessed August 11, 2019.Google Scholar
4. Carbon, M, Hsieh, CH, Kane, JM, Correll, CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78(3): e264–e278.Google Scholar
5. Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21(2): 151–156.Google Scholar
6. Woods, SW, Morgenstern, H, Saksa, JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010; 71(4): 463–474.Google Scholar
7. Kane, JM, Smith, JM. Tardive dyskinesia: prevalence and risk factors, 1959 to1979. Arch Gen Psychiatry. 1982; 39(4): 473–481.Google Scholar
8. Ganguli, R, Strassnig, M. Are older antipsychotic drugs obsolete? BMJ. 2006; 332(7554): 1346–1347.Google Scholar
9. Crystal, S, Olfson, M, Huang, C, Pincus, H, Gerhard, T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009; 28(5): w770–w781.Google Scholar
10. Monasterio, E, McKean, A. Quetiapine use: science or clever marketing? Aust N Z J Psychiatry. 2013; 47(1): 96–97.Google Scholar
11. Owens, DCG. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press; 1999.Google Scholar
12. Casey, DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000; 61(Suppl 4): 5–9.Google Scholar
13. Souza, R, Remington, G, Chowdhury, NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol. 2009; 20(10): 688–694.Google Scholar
14. Lerner, PP, Miodownik, C, Lerner, V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015; 69(6): 321–334.Google Scholar
15. Bhidayasiri, R, Fahn, S, Weiner, WJ, et al. Evidence-based guideline: treatment of tardive syndromes. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5): 463–469.Google Scholar
16. Aia, PG, Revuelta, GJ, Cloud, LJ, Factor, SA. Tardive dyskinesia. Curr Treat Options Neurol. 2011; 13(3): 231–241.Google Scholar
17. Lieberman, JA, Saltz, BL, Johns, CA, Pollack, S, Borenstein, M, Kane, J. The effect of clozapine on tardive dyskinesia. Br J Psychiatry. 1999; 158: 503–510.Google Scholar
18. Welter, ML, Grabli, D, Vidailhet, M. Deep brain stimulation for hyperkinetics disorders; dystonia, tardive dyskinesia, and tics. Curr Opin Neurol. 2010; 23(4): 420–425.Google Scholar
19. Kaur, N, Kumar, P, Jamwal, S, Deshmukh, R, Gauttam, V. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016; 23(3): 176–185.Google Scholar
20. Wimalasena, K. Vesicular monoamine transporters: structure–function, pharmacology, and medicinal chemistry. Med Res Rev. 2011; 31(4): 483–519.Google Scholar
21. Voelker, R. Tardive dyskinesia drug approved. JAMA. 2017; 317(19): 1942.Google Scholar
22. Citrome, L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication. What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017; 71(7): doi: 10.1111/ijcp.12964. Epub ahead of print May 12.Google Scholar
23. Yassa, R, Jones, BD. Complications of tardive dyskinesia: a review. Psychosomatics. 1985; 26(4): 305–313.Google Scholar
24. Lohr, JB, Caliguri, MP. Quantitative instrumental measurement of tardive dyskinesia: a review. Neuropsychopharmacology.. 1993; 6(4): 231–239.Google Scholar
25. Kuo, SH, Jankovic, J. Tardive gait. Clin Neurol Neurosurg. 2008; 110(2): 198–201.Google Scholar
26. Simpson, GM, Shrivastava, RK. Abnormal gaits in tardive dyskinesia. Am J Psychiatry. 1978; 135(7): 865.Google Scholar
27. Yassa, R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989; 80(1): 64–67.Google Scholar
28. Lauterbach, EC, Singh, H, Simpson, GM, Morrison, RL. Gait disorders in tardive dyskinesia. Acta Psychiatr Scand. 1990; 82(3): 267.Google Scholar
29. Montero-Odasso, M, Verghese, J, Beauchet, O, Hausdorff, JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012; 60(11): 2127–2136.Google Scholar
30. Van Emmerik, RE, Sprague, RL, Newell, KM. Quantification of postural sway patterns in tardive dyskinesia. Mov Disord. 1993; 8(3): 305–314.Google Scholar
31. Ko, YG, Van Emmerik, RE, Sprague, RL, Newell, KM. Postural stability, tardive dyskinesia and developmental disability. J Intellect Disabil Res. 1992; 36(Pt 4): 309–323.Google Scholar
32. Leavy, B, Byberg, L, Michaëlsson, K, Melhus, H, Åberg, AC. The fall descriptions and health characteristics of older adults with hip fracture: a mixed methods study. BMC Geriatr. 2015; 15: 40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428087/. Accessed August 11, 2017.Google Scholar
33. Liu-Ambrose, T, Khan, KM, Donaldson, MG, Eng, JJ, Lord, SR, McKay, HA. Falls-related self-efficacy is independently associated with balance and mobility in older women with low bone mass. J Gerontol A Biol Sci Med Sci. 2006; 61(8): 832–838.Google Scholar
34. Blanchet, PJ, Rompre, PH, Lavinge, GJ, Lamarche, C. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005; 18(1): 10–19.Google Scholar
35. Achiron, A, Melamed, E. Tardive eating dystonia. Mov Disord. 1990; 5(4): 331–333.Google Scholar
36. Girard, P, Monette, C, Normandeau, L, et al. Contribution of orodental status to the intensity of orofacial tardive dyskinesia: an interdisciplinary and video-based assessment. J Psychiatr Res. 2012; 46(5): 684–687.Google Scholar
37. Lumetti, S, Ghiacci, G, Macaluso, GM, et al. Tardive dyskinesia, oral parafunction, and implant-supported rehabilitation. Case Rep Dent. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168480/. Accessed August 11, 2017.Google Scholar
38. Portnoy, RA. Hyperkinetic dysarthria as an early indicator of impending tardive dyskinesia. J Speech Hear Disord. 1979; 44(2): 214–219.Google Scholar
39. Myers, DE, Schooler, NR, Zullo, TG, Levin, H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J Prosthet Dent. 1993; 69(6): 578–581.Google Scholar
40. Samie, MR, Dannenhoffer, MA, Rozek, S. Life-threatening tardive dyskinesia caused by metroclopramide. Mov Disord. 1987; 2(2): 125–129.Google Scholar
41. Greenberg, DB, Murray, GB. Hyperventilation as a variant of tardive dyskinesia. J Clin Psychiatry. 1981; 42(10): 401–403.Google Scholar
42. Chiang, E, Pitts, WM Jr, Rodriguez-Garcia, M. Respiratory dyskinesia: review and case reports. J Clin Psychiatry. 1985; 46(6): 232–234.Google Scholar
43. Horiguchi, J, Shingu, T, Hayashi, T, et al. Antipsychotic-induced life-threatening “esophageal dyskinesia.”. Int Clin Psychopharm. 1999; 14(2): 123–127.Google Scholar
44. Clark, GT, Ram, S. Orofacial movement disorders. Oral Maxillofac Surg Clin North Am. 2016; 28(3): 397–407.Google Scholar
45. Caliguri, MP, Teulings, HL, Dean, CE, Lohr, JB. A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. J Clin Psychopharmacol. 2015; 35(2): 168–174.Google Scholar
46. Neelam, K, Garg, D, Marshall, M. A systematic review and meta-analysis of neurological soft signs in relatives of people with schizophrenia. BMC Psychiatry.. 2011; 11: 139. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173301/. Accessed August 11, 2017.Google Scholar
47. Burton, BK, Hjorthøj, C, Jepsen, JR, Thorup, A, Nordentoft, M, Plessen, KJ. Research review: do motor deficits during development represent an endophenotype for schizophrenia? A meta-analysis. J Child Psychol Psychiatry. 2016; 57(4): 446–456.Google Scholar
48. Strassnig, M, Cornacchio, D, Harvey, PD, Kotov, R, Fochtmann, L, Bromet, EJ. Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. J Psychiatr Res. 2017; 94: 180–185.Google Scholar
49. Vrtunski, PB, Alphs, LD, Meltzer, HY. Isometric force control in schizophrenia patients with tardive dyskinesia. Psychiatry Res. 1991; 37(1): 57–72.Google Scholar
50. Strassnig, M, Brar, JS, Ganguli, R. Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophr Res. 2011; 126(1–3): 103–109.Google Scholar
51. Waddington, JL, O’Callaghan, E, Larkin, C, Kinsella, A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn. 1993; 23(1): 56–70.Google Scholar
52. Waddington, JL, Youssef, HA, Dolphin, C, Kinsella, A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia: their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry. 1987; 44(10): 907–912.Google Scholar
53. Waddington, JL, Youssef, HA, Kinsella, A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med. 1990; 20(4): 835–842.Google Scholar
54. Baribeau, J, Laurent, JP, Décary, A. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach. Brain Cogn. 1993; 23(1): 40–55.Google Scholar
55. Spohn, HE, Coyne, L. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Brain Cogn. 1993; 23(1): 28–39.Google Scholar
56. DeWolfe, AS, Ryan, JJ, Wolf, ME. Cognitive sequelae of tardive dyskinesia. J Nerv Ment Dis. 1988; 176(5): 270–274.Google Scholar
57. Byne, W, White, L, Parella, M, Adams, R, Harvey, PD, Davis, KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriatr Psychiatry. 1998; 13(7): 473–479.Google Scholar
58. Pourcher, E, Cohen, H, Cohen, D, Baruch, P, Bouchard, RH. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Brain Cogn. 1993; 23(1): 81–87.Google Scholar
59. Sachdev, P, Hume, F, Toohey, P, Doutney, C. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatr Scand. 1996; 93(6): 451–459.Google Scholar
60. Struve, FA, Willner, AE. Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry. 1983; 143: 597–600.Google Scholar
61. Wegner, JT, Kane, JM, Weinhold, P, Woerner, M, Kinon, B, Lieberman, J. Cognitive impairment in tardive dyskinesia. Psychiatry Res. 1985; 16(4): 331–337.Google Scholar
62. Wu, JQ, Chen, DC, Xiu, MH, et al. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46: 71–77.Google Scholar
63. Krabbendam, L, van Harten, PN, Picus, I, Jolles, J. Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curaçao Extrapyramidal Syndromes Study: IV. Schizophr Res. 2000; 42(1): 41–46.Google Scholar
64. Miller, DD, McEvoy, JP, Davis, SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005; 80(1): 33–43.Google Scholar
65. Sarro, S, Pomarol-Clotet, E, Canales-Rodriguez, EJ, et al. Structural brain changes associated with tardive dyskinesia in schizophrenia. Br J Psychiatry. 2013; 203(1): 51–57.Google Scholar
66. Pantelis, C, Stuart, GW, Nelson, HE, Robbins, TW, Barnes, TR. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry. 2001; 158(8): 1276–1285.Google Scholar
67. Emsley, R, Niehaus, DJ, Oosthuizen, PP, Koen, L, Chiliza, B, Fincham, D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry. 2011; 26(5): 293–296.Google Scholar
68. Arango, C, Adami, H, Sherr, JD, Thaker, GK, Carpenter, WT Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry. 1999; 156(7): 1097–1099.Google Scholar
69. Emsley, R, Niehaus, DJH, Oosthuizen, L, Koen, L, Chiliza, B, Fincham, D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry. 2011; 26(5): 293–296.Google Scholar
70. Myslobodsky, MS, Tomer, R, Holden, T, Kempler, S, Sigal, M. Cognitive impairment in patients with tardive dyskinesia. J Nerv Ment Dis. 1985; 173(3): 156–160.Google Scholar
71. Macpherson, R, Collis, R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992; 160: 110–112.Google Scholar
72. Gould, F, McGuire, LS, Durand, D, et al. Self-assessment in schizophrenia: accuracy of evaluation of cognition and everyday functioning. Neuropsychology. 2015; 29(5): 675–682.Google Scholar
73. Meltzer, HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry. 1998; 59(Suppl 3): 15–20.Google Scholar
74. Hierholzer, RW. Tardive dyskinesia with complaints of pain. Am J Psychiatry. 1989; 146(6): 802.Google Scholar
75. Earle, J Jr, Patterson, WM. Chronic pain, neuroleptics, and tardive dyskinesia. Psychosomatics. 1986; 27(4): 291–293.Google Scholar
76. Blanchet, PJ, Popovici, R, Guitard, F, Rompré, PH, Lamarche, C, Lavigne, GJ. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord. 2008; 23(13): 1837–1842.Google Scholar
77. Schoonderwoerd, K. Chiropractic management of musculoskeletal pain secondary to tardive dyskinesia. J Can Chiropr Assoc. 2005; 49(2): 92–95.Google Scholar
78. Jeste, DV, Caliguri, MP. Tardive dyskinesia. Schizophr Bull. 1993; 19(2): 303–315.Google Scholar
79. Strassnig, M, Signorile, J, Gonzalez, C, Harvey, PD. Physical performance and disability in schizophrenia. Schizophr Res Cogn. 2014; 1(2): 112–121.Google Scholar
80. Yassa, R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand. 1989; 80(1): 64–67.Google Scholar
81. Dean, CE, Russell, JM, Kuskowski, MA, Caligiuri, MP, Nugent, SM. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol. 2004; 24(3): 298–304.Google Scholar